EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Transdermal oestradiol and exercise in androgen deprivation therapy ( ESTRACISE ): protocol

Ilkka Jussila iD, Juha P Ahtiainen iD, Eija K Laakkonen iD, Aino Siltari iD, Antti Kaipia, Tiina Jokela iD, Minta Kärkkäinen iD, Rob Newton iD, Truls Raastad iD, Heini Huhtala iD, Teemu J Murtola iD, Heikki Seikkula iD

BJU International · 2024

DOI: 10.1111/bju.16361 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BJU International, 2024. Verfasst von Ilkka Jussila und 11 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Clinic, Wellbeing Services County of Central Finland, Jyvaskyla, Finland. Hauptthemen laut MEDLINE: Administration, Cutaneous, Androgen Antagonists, Estradiol, Exercise Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Government Research Funding, Syöpäsäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report the protocol of a study evaluating the efficacy of transdermal oestradiol (E2) gel in reducing the adverse effects of androgen deprivation therapy (ADT), specifically on sexual function, and to assess the utility of E2 in combination with supervised exercise. Study Design and Methods The primary endpoint of this open‐label Phase IIA randomized controlled trial is the efficacy of transdermal E2 gel. Secondary endpoints include: (i) the occurrence of ADT‐induced adverse effects; (ii) the safety and tolerability of E2; (iii) the impact of E2 with or without exercise on physical, physiological, muscle, and systemic biomarkers; and (iv) quality of life. The trial will recruit high‐risk PCa patients ( n = 310) undergoing external beam radiation therapy with adjuvant subcutaneous ADT. Participants will be stratified and randomized in a 1:1 ratio to either the E2 + ADT arm or the ADT‐only control arm. Additionally, a subset of patients ( n = 120) will be randomized into a supervised exercise programme.

Results

The primary outcome is assessed according to the efficacy of E2 in mitigating the deterioration of Expanded Prostate Cancer Index Composite sexual function domain scores. Secondary outcomes are assessed according to the occurrence of ADT‐induced adverse effects, safety and tolerability of E2, impact of E2 with or without exercise on physical performance, body composition, bone mineral density, muscle size, systematic biomarkers, and quality of life.

Conclusion

The ESTRACISE study's innovative design can offer novel insights about the benefits of E2 gel, and the substudy can reinforce the benefits resistance training and deliver valuable new novel insights into the synergistic benefits of E2 gel and exercise, which are currently unknown. Trial Registration The protocol has been registered in euclinicaltrials.eu (2023‐504704‐28‐00) and in clinicaltrials.gov (NCT06271551).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, CutaneousAndrogen AntagonistsEstradiolExercise TherapyProstatic NeoplasmsHumansMaleClinical Trials, Phase II as TopicCombined Modality TherapyQuality of LifeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

androgen deprivation therapyexerciseprostate cancerresistance trainingtransdermal oestradiol

Substanzen

Androgen AntagonistsEstradiol

Autor:innen und Institutionen

  • Surgery Clinic, Wellbeing Services County of Central Finland, Jyvaskyla, Finland.
  • Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Urology, TAYS Cancer Center, Tampere, Finland.
  • Sports Science and Exercise Medicine, Edith Cowan University, Joondalup, WA, Australia.
  • Department of Physical Performance, Norwegian School of Sport Sciences, Norwegian, Norway.

ORCID-Profile: Ilkka Jussila, Juha P Ahtiainen, Eija K Laakkonen, Aino Siltari, Tiina Jokela, Minta Kärkkäinen, Rob Newton, Truls Raastad, Heini Huhtala, Teemu J Murtola, Heikki Seikkula

Förderung

  • Government Research Funding
  • Syöpäsäätiö

Zitieren

APA

Jussila, I., Ahtiainen, J. P., Laakkonen, E. K., Siltari, A., Kaipia, A., Jokela, T., Kärkkäinen, M., Newton, R., Raastad, T., Huhtala, H., Murtola, T. J., & Seikkula, H. (2024). Transdermal oestradiol and exercise in androgen deprivation therapy ( ESTRACISE ): protocol. BJU International. https://doi.org/10.1111/bju.16361

Vancouver

Jussila I, Ahtiainen JP, Laakkonen EK, Siltari A, Kaipia A, Jokela T, et al. Transdermal oestradiol and exercise in androgen deprivation therapy ( ESTRACISE ): protocol. BJU International. 2024. doi:10.1111/bju.16361

BibTeX
@article{Jussila2024,
  author = {Jussila, Ilkka and Ahtiainen, Juha P and Laakkonen, Eija K and Siltari, Aino and Kaipia, Antti and Jokela, Tiina and Kärkkäinen, Minta and Newton, Rob and Raastad, Truls and Huhtala, Heini and Murtola, Teemu J and Seikkula, Heikki},
  title = {Transdermal oestradiol and exercise in androgen deprivation therapy ( ESTRACISE ): protocol},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16361}
}
Kostenlos starten →